Search results
Teva Pharmaceutical’s stock climbs as schizophrenia treatment shows promise
Market Watch· 10 hours agoTeva Pharmaceutical Industries stock jumped more than 6% early Wednesday after the company reported...
'Impressive' New Data on Novel Schizophrenia Hopeful KarXT
Medscape· 18 hours agoThe novel investigational antipsychotic KarXT was effective and well tolerated in adults with ...
Teva Pharma's Turnaround Story: How A Key Win Helped It Clinch A Five-Year High
Investor's Business Daily· 3 hours agoTeva stock surged to a five-year high Wednesday after the company beat first-quarter expectations...
Teva Stock Powers Ahead as Schizophrenia News Offsets Mixed Earnings
Barrons.com· 5 hours agoShares of Teva Pharmaceutical Industries were climbing yet again on Wednesday, after the company...
Teva, Medincell's schizophrenia drug succeeds in late-stage study
Reuters via Yahoo News· 13 hours agoU.S.-listed shares of Teva were up 3.3% at $14.41 in premarket trading. The companies hope that the...
Cat owners could be at higher risk of schizophrenia, study suggests
FOX 10 Phoenix· 5 hours agoThe report, released by researchers from the University of Queensland in Australia, implies that...
Nottingham killer Valdo Calocane’s paranoid schizophrenia ‘not caused by drugs’
Daily Telegraph· 7 hours agoEmma Webber, Barnaby’s mother, said the families recognised that Calocane was unwell, but he was not...
Nottingham killer Valdo Calocane ‘must never be released just like Ian Brady’
Daily Telegraph· 7 hours agoMr Joyce said Calocane had been suffering from paranoid schizophrenia since 2019 and was formally...
Teva stock gains on trial win, Q1 beat (NYSE:TEVA)
Seeking Alpha· 9 hours agoTeva Pharmaceutical (TEVA) stock posts record gains due to better-than-expected Q1 revenue and positive Phase 3 trial results for its schizophrenia drug....
...olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia -...
Benzinga· 13 hours agoThe study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘749 dose groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total